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Abstract 
 
Background and Aims:  
Vascular disease is a common comorbidity in Parkinson’s disease (PD) 
patients. Statins are potentially neuroprotective for PD through non-vascular 
mechanisms. We investigated prevailing statin use in a PD cohort. 
 
Methods and Results: 
Data on diagnostic indication for statins, antiparkinson therapy, vascular risk 
factors, and statin prescription, were obtained from electronic medical record 
review for consecutive PD patients. The ASSIGN (ASsessing cardiac risk 
using Scottish Intercollegiate Guidelines Network) system was used to 
calculate future cardiovascular risk, and identify those warranting statin use. 
Of 441 patients included, 59.9% were male, with a mean age of 68.9 years 
(SD 10.3). 174 patients (39.5%) had at least one diagnostic indication for 
statin use, of whom 136 (78.2%) were prescribed a statin. In the 267 cases 
(60.5%) without a diagnostic indication, 54 (20.2%) were excluded owing to 
age-limitations defined in ASSIGN. Of the remaining 213, 62 (29.1%) had an 
ASSIGN score in the recommended range for statin therapy, of whom 15 
(24.1%) were prescribed statins.  
 
Conclusion: 
There is suboptimal implementation of statin therapy in PD patients. Given the 
possible neuroprotective effects of statins in PD in addition to reducing 
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cardiovascular risk, reasons for suboptimal implementation warrant further 
investigation. 




Parkinson’s disease, statin, cardiovascular disease, cardiovascular risk, 
neuroprotection.
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Background 
 
Parkinson’s disease (PD) and cerebrovascular disease (CVD) both increase 
significantly with age and have overlapping symptomatology, in particular for 
cognition and gait impairment. PD patients with vascular risk factors, or brain 
imaging features of subclinical CVD, have greater gait impairment and worse 
motor symptoms, which has implications for prognosis and treatment 1-4.  
 
Statins are proven to reduce the risk of vascular events when used as 
secondary preventive treatment (eg. after ischaemic stroke or myocardial 
infarction) or in the presence of a high future vascular risk as primary 
prevention 5, 6. The known adverse effects of CVD on cognition and gait are 
likely to contribute to morbidity in PD, and might be diminished by optimising 
the implementation of statins and other vascular preventive treatment 
approaches.  
 
Cholesterol is also implicated in neurodegenerative diseases including PD, 
being associated with several neuropathological processes 7, 8. The potential 
of statins as neuroprotective for PD is increasingly recognised, and a UK-
based study (PD-STAT) is underway; this randomises PD patients to high-
dose statin or placebo, when statin therapy is not indicated by increased 
vascular risk 9.  
 
In view of the possible advantages of statin use in PD patients as described 
above, we sought to establish statin usage rates in a clinic-based cohort of 
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PD patients, to define rates of vascular comorbidity and risks, and assess the 
implementation of cholesterol-lowering therapy according to Scottish 
guidelines. 
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Methods 
 
Drug-treated PD patients, aged over 18 years, diagnosed clinically but with 
diagnoses supported by structural and dopaminergic functional neuroimaging 
performed on clinical grounds were included. This was a convenience sample 
of all consecutive cases attending the regional movement disorder clinic 
between February 2008 and March 2015. Patient demographics and 
characteristics, laboratory results and list of medications were obtained from 
electronic medical records. The study was approved by the clinical 
governance office of the local Health Board.  
 
Standard diagnostic indications for statin use (cardiovascular, cerebrovascular, 
chronic kidney disease, diabetes and peripheral vascular disease [PVD]) were 
identified from coding and clinical records. For cases without a diagnostic 
indication for statin therapy, the 10-year cardiovascular risk was calculated 
using the ASsessing cardiac risk using Scottish Intercollegiate Guidelines 
Network (ASSIGN) scoring system, version 1.5.110. Where information on 
smoking, systolic blood pressure, total and HDL cholesterol was unavailable, 
mean values based on age and sex for each parameter, and calculated by the 
ASSIGN scoring system, were imputed. 169 (79.3%) patients had data on 
their systolic blood pressure, 151 (70.9%) on total cholesterol, 142 (66.7%) on 
HDL cholesterol, 169 (79.3%) on smoking habits and 199 (93.4%) on 
estimated glomerular filtration rate. ASSIGN is applicable to patients aged 30 
to 74 years who do not have diagnostic indication for statins 11. A cut-off for 
ASSIGN of 20% or more as a vascular risk score warranting statin therapy 
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was used, based on current recommendations 11, and in addition, an 
exploratory calculation was based on an ASSIGN score of 10% or more, 
given recent downward adjustment of the recommendation level from 20% to 
10% for the similar QRISK vascular risk calculator, in England and Wales 12. 
Diabetes is not considered a risk factor in the current study as it is already 
considered as an indication for statin use by ASSIGN. The L-dopa equivalent 




Chi-square tests were used for categorical data (and for trend when 
appropriate), 2 sample t-tests and ANOVA for parametric data and Mann-
Whitney U and Kruskal-Wallis test for non-parametric data. Correction for 
confounding variables was performed with bivariate and partial correlations. 
SPSS 22 (SPSS Inc., Chicago, IL, USA) was used. Statistical significance 
was set at P<0.05. 
  9 
Results 
 
Out of 441 patients with PD and prescribed antiparkinson therapy, 174 (39.5%) 
had one or more diagnostic indication for statin therapy, and 54 patients 
(12.2%) were aged over 74 years, leaving 213 patients (48.2%) for ASSIGN 
vascular risk calculation. The majority of patients were male (59.9%) with a 
mean age of 68.9 years (SD 10.3). The most common vascular risk factor was 
hypertension (32.9%). Levodopa-based therapy was used by the majority of 
patients (94.6%). 43.8% of PD patients were prescribed statins, most commonly 
simvastatin.  
 
Vascular risk factors and medication use were assessed according to diagnostic 
indication for statin use (Table 1). Patients with a diagnostic indication for statin 
use were significantly older by approximately 7 years (p<0.0005). A significantly 
higher proportion of patients with a diagnostic indication for statins had smoked 
tobacco, had hypertension, were prescribed statin and antiplatelet therapy, 
even after age adjustment compared to patients without any diagnostic 
indication for statin use (Table 1).  Patients with a diagnostic indication for statin 
use were significantly less likely to be prescribed mono-amine oxidase type B 
inhibitors (5.2% vs. 15.4%, p=0.001) (Table 1).    
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Of patients with a diagnostic indication for statin use, 69.0% had a single 
indication (Table 2). Considering the indication, 80.0% of patients with cardiac 
disease, 76.5% with diabetes and 71.9% with CVD were prescribed statins. 
Neither of 2 patients with PVD as their only diagnostic indication was prescribed 
a statin.  
 
Figure 1 shows the breakdown of PD patients who were prescribed 
antiparkinson therapy. 174 patients had a diagnostic indication for statin use, 
the most common being cardiac disease. Of these patients, 78% patients were 
prescribed statins. Of the 213 patients eligible for ASSIGN calculation, 10% 
patients with low risk (ASSIGN ≤ 10), 19% with moderate risk (ASSIGN 11-19) 
and 24% with high risk (ASSIGN ≥ 20) were prescribed statins. 
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Discussion 
 
This is the first paper reporting the use of statins in PD patients in Scotland. 
We report that a high proportion of patients with a diagnostic indication 
received statin therapy, but that the proportion of patients with a high future 
cardiovascular risk being treated with statins was considerably lower.  
 
Our results are consistent with other studies performed in a more general 
population; namely higher rates of statin use in those with a diagnostic 
indication than in those with a risk status indication. A UK survey showed that 
93% of patients with coronary disease and 61% of high-risk individuals (by a 
definition including elevated cholesterol) were treated with statins 14. 
European studies have reported that 81% of coronary patients and 47% of 
patients with elevated total cholesterol were treated with statins 15, 16. 
Although one study from Italy found the same rate of 61% for statin use for 
both patients with established CVD and patients with high future risk of CVD, 
the latter category was defined by the presence of hyperlipidemia rather than 
using a risk calculator, which may explain the higher statin use17. Some of the 
differences observed between studies can be explained by patient 
demographics and variable methods of defining risk, through risk calculators 
in some studies or according to the prescription of anti-hypertensive, anti-
diabetic or lipid-lowering drugs in other studies. Our patient cohort was 
approximately 8 years older than those in the studies described above 13-16 
and fewer were current cigarette smokers, which is expected given the known 
greater prevalence of PD in non-smokers 18-21. Our study findings are also 
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similar to those from a UK PD cohort, which showed underutilisation of statins 
(75.3% in patients with CVD, 37.2% in patients with high vascular risk and 
15.1% in patients with medium vascular risk) in PD patients where risk was 
assessed using QRISK2 3. Our cohort had fewer patients with high vascular 
risk who were treated with statins compared with the UK study. There are 
however, differences in the ASSIGN guidelines used in Scotland compared to 
QRISK2 guidelines used in the rest of UK, so direct comparison of these 
findings is not straightforward. 
 
Reasons for sub-optimal statin implementation, particularly in the ‘at risk’ 
group, deserve further consideration. Patient choice (to take statin therapy or 
not), therapy persistence (maintenance of treatment once initiated) and 
awareness and perception of guidelines are all potential factors 22, 23. A more 
PD-specific reason for suboptimal implementation of statins is the well-known 
potential side-effect of muscle pain or cramp, which is a very common 
symptom from PD, and may be difficult to distinguish from a statin effect. 
Given that myalgia occurs in only about 10% of those taking statins 24, it is 
possible that over-attribution of muscle pain to statins occurs in PD patients, 
and we plan to examine this in a more detailed multicentre study. 
 
In conclusion, a significant proportion of PD patients, particularly those with a 
high CVD risk that may benefit from statin therapy, are not prescribed such 
treatment. Given the potential neuroprotective benefits from statins in PD in 
addition to established reductions in cardiovascular risk, the reasons for this 
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under-utilisation merit further study, which could be achieved in an 
observational design. 
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Table 1: Demographics, vascular risks, and antiparkinson drug use in 441 Parkinson’s disease patients. 
Characteristic Diagnostic indication for statin All patients 
Yes No p-value Adjusted p-valuea  
Number of patients 174 (39.5%) 267 (60.5%)   441 
Male sex 59.8% 59.9% 1.000 0.124 59.9% 
Age, Mean (SD) 73.2 (9.1) 66.0 (10.0) <0.0005  68.9 (10.3) 
Smoking status      
 Ever smokers 40.8% 27.0% 0.014 0.008 32.4% 
 Current smokers 8.6% 9.4% 0.791 0.294 9.1% 
Risk Factors      
 Hypertension 49.4% 22.1% <0.0005 <0.0005 32.9% 
 Atrial fibrillation 8.6% 3.0% 0.009 0.235 5.2% 
 Heart failure 1.7% 0.4% 0.305 0.504 0.9% 
 Rheumatoid arthritis 1.1% 0.7% 0.665 0.894 0.9% 
Antiparkinson drug type     
 Levodopa + DDI 97.7% 92.5% 0.019 0.168 94.6% 
  17 
 Dopamine agonists 27.6% 41.6% 0.003 0.523 36.1% 
 COMT inhibitors 14.9% 22.1% 0.063 0.124 19.3% 
 MAOB inhibitors 5.2% 15.4% 0.001 0.024 11.3% 
 Amantadine 4.0% 6.4% 0.289 0.751 5.4% 
 Anticholinergics 2.3% 0.7% 0.170 0.126 1.4% 
LEDD, median (IQR) 400 (200-600) 450 (260-700) 0.076 0.340 400 (250-665) 
Medication       
 Statin therapy 78.2%  21.3% <0.0005 <0.0005 43.8% 
  Simvastatin 48.9% 16.5%   29.3% 
  Atorvastatin 23.0% 4.1%   11.6% 
  Rosuvastatin 3.4% 0.4%   1.6% 
  Pravastatin 2.3% 0.4%   1.1% 
  Fluvastatin 0.6% 0%   0.2% 
 Non-statin therapy  2.9% 0.7% 0.081 0.069 1.6% 
 Antiplatelets  71.8% 16.1% <0.0005 <0.0005 38.1% 
 Anticoagulants 12.1% 4.5% 0.003 0.137 7.5% 
  18 
aadjusted for age 
SD = standard deviation, DDI = dopa decarboxylase inhibitor, IQR = interquartile range, COMT = catechol-O-methyl transferase, MAOB = 
monoamine oxidase type B, LEDD = levodopa equivalent daily dose. Non-statin includes ezetimibe and fibrates. 
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Table 2: Demographics and medication use in 174 patients with Parkinson’s 
disease, who had one or more diagnostic indication for statin use. 
 
Characteristic 1 indication  
(N=120, 69.0%) 




Age, mean (SD) 72.9 (9.3) 73.9 (8.6) 0.682 
Male sex  58.3% 63.0% 0.620 
Smoking status    
 Ever smokers 41.2% 55.8% 0.122 
 Current smokers 10.8% 3.7% 0.208 
Antiparkinson drug classes  0.719 
 1 61.7% 61.1%  
 2 29.2% 25.9%  
 ≥ 3 9.2% 13.0%  
LEDD, median (IQR) 300 (200-600) 410 (300-798) 0.047 
Statin use 74.2% 87.0% 0.089 
SD = standard deviation, LEDD = levodopa equivalent daily dose, IQR = interquartile 
range
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Figure 1: Flow chart for 441 patients with Parkinson’s disease and prescribed 
antiparkinson therapy. Patients with a diagnostic indication for statin therapy 
were identified, and the cardiovascular risk score was assessed in remaining 
patients. The proportions in each category who were prescribed statins were 
calculated. PD = Parkinson’s disease, PVD = peripheral vascular disease, 
CKD = chronic kidney disease, ASSIGN = ASsessing cardiac risk using 
Scottish Intercollegiate Guidelines Network 
 
  
 
